|
Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy Clinical research trials and Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy. Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy clinical trial. Human subjects frequently get the finest healthcare available for their Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy  Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
For Condition: ovarian epithelial cancer,Breast Cancer,Testicular Cancer,kidney tumor,Multiple Myeloma,Leukemia,Lymphoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: Antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known which antibody therapy regimen is more effective for graft-versus-host disease. PURPOSE: Randomized phase II/III trial to compare the effectiveness of two different antibody therapy regimens in treating patients who have graft-versus-host disease that does not respond to steroid therapy.
Details: OBJECTIVES: I. Compare the 180 day survival and overall survival of patients with steroid resistant acute graft-versus-host disease (GVHD) treated with ABX-CBL versus anti-thymocyte globulin. II. Compare the efficacy of these drugs in this patient population. III. Compare the safety of these drugs in this patient population. IV. Compare the long term endpoints, such as the development of new malignancies, the onset of serious infections, or chronic GVHD, in patients treated with these drugs. V. Determine the toxicity of ABX-CBL in these patients. PROTOCOL OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to International Bone Marrow Transplant Registry severity index (index B or C vs index D). Patients are randomized to one of two treatment arms. Arm I: Patients receive ABX-CBL IV over 2 hours on days 1-14. Treatment continues as twice weekly infusions for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive anti-thymocyte globulin IV on days 3, 5, 7, 9, 11, and 13. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at 100 days, monthly for at least 3 months, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 92 patients (46 per arm) will be accrued for this study within 12-15 months.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 1 Year/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of steroid resistant acute graft-versus-host disease (GVHD) with an International Bone Marrow Transplant Registry severity index of B, C, or D - No chronic GVHD Receiving high-dose steroids, such as prednisone, since diagnosis of acute GVHD and for no more than 14 total days - No changes to prophylactic regimen for acute GVHD within the past 72 hours except for changes to maintain proper serum levels, or changes due to toxicity Recipient of a single allogeneic bone marrow, peripheral blood stem cell, or cord blood transplant from any donor type within the past 68 days - No second stem cell transplantation or subsequent donor cell product transplantation prior to and during study --Prior/Concurrent Therapy-- Biologic therapy: - See Disease Characteristics - No prior murine product (exposure of donor cells to a murine product allowed) - At least 5 days since prior anti-thymocyte globulin after stem cell transplantation Chemotherapy: Not specified Endocrine therapy: - See Disease Characteristics - Prior steroids for immunosuppression allowed - No other prior immunosuppressants Radiotherapy: Not specified Surgery: Not specified Other: - At least 30 days since prior investigational agents* - No other concurrent investigational agents* [Note: *Investigational antifungals allowed] --Patient Characteristics-- Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: See Cardiovascular Renal: - Creatinine no greater than 2.5 times upper limit of normal OR - No requirement of renal dialysis Cardiovascular: No severe veno-occlusive disease exhibiting at least 2 of the following: - Right upper quadrant tenderness - Weight gain of 5% or more since initiation of conditioning regimen together with ascites - Bilirubin greater than 12 mg/dL Pulmonary: - No need to maintain an 02 saturation greater than 90% with an FIO2 of greater than 50% OR - No need for ventilator support Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 4 months after study - HIV negative - No history of alcohol or substance abuse - No medical, psychiatric, or laboratory abnormality that would preclude study - No multi-organ system failure - No active systemic infection associated with greater than 60% short-term mortality such as: *Invasive mold infections (e.g., aspergillus or rhizopus) *Any lower respiratory tract infection caused by respiratory syncytial virus or parainfluenza *Any invasive infection with no approved therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MaryTerrito, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068482; ABX-CB-9906,UCLA-9911052,NCI-G01-1916
Study Start Date: March 2001
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012077
Other Lymphoma Studies:
1. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
2. Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
3. Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
4. Phase I Study of SU006668 in Patients With Advanced Solid Tumors
5. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Related Studies:
Other Lymphoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
|
|
|
|
|
|
|
|
